Sign up online today & collaborate
or click here to find out more
Cambridge, UK – Re-Pharm, an early-stage drug discovery and development company based on the principles of compound re-profiling, is pleased to announce a second UK patent on the re-purposed compound RP0217 for the treatment of ophthalmic indications.
“RP0217 is an existing marketed drug, with wide clinical use for largely systemic indications,” explains Dr Robert Scoffin, CEO at Re-Pharm. “We used the Cresset molecular design workbench Forgeto identify RP0217 as having potential against a novel target in a recently elucidated key inflammatory pathway. Screening and pre-clinical validations have confirmed RP0217 as a potent anti-inflammatory agent and to confirm a synergy with exogenous glucocorticoids, which leads to a ‘steroid sparing’ strategy with a co-formulation of RP0217 plus a steroid.”
“Re-Pharm is actively looking for partners to progress the compound through early clinical development and clinical trials,” adds Scoffin. “Since RP0217 is a re-purposed compound there is a significant body of safety data available, and we expect this to result in a shortened route to regulatory approval.”
|Contact Name||Sue Peffer|
|Contact Telephone||01223 858890|